Company record
Boehringer Ingelheim Pharmaceuticals, Inc.
0 FDA warning letters since 2023 and 1 recall in the last 12 months.
Get an email the day FDA posts anything new about Boehringer Ingelheim Pharmaceuticals, Inc..
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Jul 8 | Class II | Boehringer Ingelheim Pharmaceuticals, Inc. Drug |
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA… CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product. |